louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01838525: Alpha-1-acid Glycoprotein as a Biomarker of Developmental Diagnosing and Monitoring Effectiveness in Sepsis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Systemic Inflammatory Response Syndrome
Sepsis
Keywords: sepsis
alpha-1-acid glycoprotein (AGP)
diagnosis
prognosis
SIRS
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2013-04-24
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Between April 2011 and APRIL 2013, inpatients were included who were in the intensive care units (ICU) of the Department of Respiratory Disease (RICU), the Emergency Department (EICU), and the Department of Surgery (SICU) of the Chinese People's Liberation Army General Hospital.

Brief summary: To assess the potential value of alpha-1-acid glycoprotein (AGP) for early diagnosis and prognosis of patients with sepsis, and then compared with C-reactive protein (CRP), procalcitonin (PCT), white blood cell (WBC) counts, Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score. 164 patients were enrolled in the study, including 25 cases with systemic inflammatory response syndrome (SIRS) and 139 cases with different levels of sepsis (46 moderate sepsis, 52 severe sepsis and 41 septic shock ). Serum levels of Alpha-1-acid Glycoprotein (AGP), C-reactive protein (CRP), and procalcitonin (PCT), and white blood cell (WBC) counts were measured on the day of admission to intensive care unit (ICU).


Eligibility criteria: Inclusion Criteria:

1. Male and female aged 18 years old and over;
2. Clinically suspected infection;
3. Fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °C or lower than 36 °C (b)respiratory rate above 20/min, or PCO2 below 32 mmHg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands;

Exclusion Criteria:

1. less than 18 years old;
2. immunosuppression;
3. agranulocytosis (granulocyte counts \<0.5× 109/L);
4. chronic myeloid leukemia (CML);
5. malignancy;
6. less than 24 hours of the length of ICU stay;
7. reluctant to participate in the study.

Primary outcomes:
measure: Patients Outcome
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
state: Beijing
Study officials:
affiliation: Department Of Respiratory Diseases, Chinese PLA General Hospital
name: Lixin Xie, doctor
role: STUDY_DIRECTOR
References:
citation: Xiao K, Su L, Yan P, Han B, Li J, Wang H, Jia Y, Li X, Xie L. alpha-1-Acid glycoprotein as a biomarker for the early diagnosis and monitoring the prognosis of sepsis. J Crit Care. 2015 Aug;30(4):744-51. doi: 10.1016/j.jcrc.2015.04.007. Epub 2015 Apr 17.
Clinical trial NCT00621725: Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
Official title: A Phase I, Open Label Study of the Pharmacokinetics and Safety of Cediranib (RECENTINTM, AZD2171) Following Single and Multiple Oral Doses in Patients With Advanced Solid Tumours With Various Degrees of Hepatic Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Cancer
Hepatic Impairment
Keywords: Advanced cancer
metastatic
hepatic impairment
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-02-22
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Advanced solid tumour (not prostate cancer) for which no standard therapy exists
* WHO performance status 0-2
* Bilirubin levels within the target range

Exclusion Criteria:

* Unstable brain/meningeal metastases
* Inadequate bone marrow reserve
* Biochemistry/haematology results outside of required ranges
* History of significant GI impairment

Primary outcomes:
measure: To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).
timeFrame: Single dose PK assessed on Day 1 of dosing
Secondary outcomes:
measure: Safety/tolerability of Cediranib (single and multiple dose PK)
timeFrame: assessed from randomisation to data cut-off (15th July 2010)
Other outcomes:
Locations:
city: København Ø
country: Denmark
facility: Research Site
city: Nijmegen
country: Netherlands
facility: Research Site
city: Rotterdam
country: Netherlands
facility: Research Site
Study officials:
affiliation: Radboud University Medical Center
name: CML van Herpen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: van Herpen CM, Lassen U, Desar IM, Brown KH, Marotti M, de Jonge MJ. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. Anticancer Drugs. 2013 Feb;24(2):204-11. doi: 10.1097/CAD.0b013e32835bd1d2.
Clinical trial NCT03992625: Clinical Outcomes for Deep Brain Stimulation
Official title: Clinical Outcomes for Deep Brain Stimulation for Parkinson Disease, Tremor, and Dystonia
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Parkinson Disease
Essential Tremor
Dystonia
Keywords: Deep brain stimulation
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2019-06-20
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients receiving deep brain stimulation for movement disorders

Brief summary: The object of this study is to longitudinally collect clinical outcomes of patients receiving deep brain stimulation for movement disorders with the objective of making retrospective comparisons and tracking of risks, benefits, and complications.


Eligibility criteria: Inclusion Criteria:

* Levodopa responsive Parkinson disease OR
* Medically refractory Essential Tremor OR
* Medically refractory Dystonia

Exclusion Criteria:

* Dementia (Mattis Dementia Rating Scale \<130)
* Structural abnormalities precluding intracranial surgery

Primary outcomes:
measure: UPDRS
timeFrame: Change in UPDRS at 1 year after DBS (from preoperative baseline).
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University in St Louis
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Mwiza Ushe, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04419025: Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
Official title: Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: COVID
Sars-CoV2
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Oxidative Stress
Keywords: Glutathione
Acetylcysteine
Oxidative stress
NAC
COVID
COVID-19
SARS-CoV2
Lead sponsor: Cambridge Health Alliance
Sponsor class: OTHER
First posted: 2020-06-05
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are assigned to one of two groups in parallel for the duration of the study.

One arm is the intervention arm - those receiving N-acetylcysteine (NAC). One arm is the control group - those not receiving N-acetylcysteine (NAC).
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

Detailed description: After being informed of the study and potential risks and benefits, patients meeting eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as follows:

Inpatients:

* N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until discharge
* N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge

Outpatients:

- N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks

Eligibility criteria: Inclusion Criteria:

* known or suspect COVID-19 disease AND one or more of the following influenza-like symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of breath chest pain

Exclusion Criteria:

* Minors, pregnant women and people unable to provide informed consent are excluded from this study

Primary outcomes:
measure: Decrease in Respiratory Rate
timeFrame: First hour after first dose of NAC
measure: Hospital length of stay (LOS)
timeFrame: Through study completion, average 9 months
measure: Need for mechanical ventilation
timeFrame: Through study completion, average 9 months
measure: Length of time intubated
timeFrame: Through study completion, average 9 months
measure: Need for hospitalization
timeFrame: Through study completion, average 9 months
measure: Recovery disposition
timeFrame: Through study completion, average 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cambridge
country: United States
facility: CHA Cambridge Hospital
state: Massachusetts
city: Everett
country: United States
facility: CHA Everett Hospital
state: Massachusetts
city: Somerville
country: United States
facility: CHA Respiratory Clinic
state: Massachusetts
city: Somerville
country: United States
facility: CHA Somerville campus
state: Massachusetts
Study officials:
References:
Clinical trial NCT04126525: Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Official title: NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Breast Cancer Female
Keywords: neoadjuvant
pyrotinib
trastuzumab
paclitaxel
cisplatin
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2019-10-15
Enrollment: 53
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.


Eligibility criteria: Inclusion Criteria:

* Female, Aged ≥18 and ≤70 years
* Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage ⅡA-Ⅲ)
* Subjects with at least one evaluable lesion
* ECOG 0-1
* Adequate organ function

Exclusion Criteria:

* Metastatic disease (Stage IV)
* Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
* Treated or treating with T-DM1, lapatinib and neratinib before study entry
* History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation
* Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial
* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test. Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
* Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study

Primary outcomes:
measure: pCR
timeFrame: 1-2 weeks after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital
Study officials:
affiliation: RenJi Hospital
name: Jinsong Lu
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yin W, Wang Y, Wu Z, Ye Y, Zhou L, Xu S, Lin Y, Du Y, Yan T, Yang F, Zhang J, Liu Q, Lu J. Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clin Cancer Res. 2022 Sep 1;28(17):3677-3685. doi: 10.1158/1078-0432.CCR-22-0446.
Clinical trial NCT04055025: Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin
Official title: Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bariatric Surgery
Keywords: Ghrelin
Sleeve gastrectomy
Laparoscopic sleeve gastrectomy
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2019-08-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Our hypothesis is that decreased concentration of ghrelin after LSG is important for the decreased appetite and food intake postoperatively. We therefore expect infusion of ghrelin will increase an ad libitum food intake after LSG. We also expect that a decreased postprandial concentration of ghrelin after LSG play a role for increased insulin secretion and decreased postprandial plasma glucose concentrations after surgery.

Detailed description: Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) are to bariatric procedure. After both procedures, a changed secretion of hormones from the gastrointestinal tract is believed to affect appetite and glucose metabolism. Studies have shown that after LRYGB, there is a significant increased secretion of GLP-1 and PYY. In contrast, a decreased secretion of ghrelin is a characteristic finding after LSG opposite post-LRYGB, where secretion of ghrelin is reported to be increased, decreased or unchanged. Ghrelin is primarily secreted from the gastric mucosa in the fasting state and decreases in response to food intake. Ghrelin stimulates food intake through appetite-regulating centers in the hypothalamus. Administration of exogenous ghrelin has been reported to stimulate appetite. In addition, ghrelin has recently been suggested also to affect glucose metabolism by inhibition of glucose-stimulated insulin secretion. Therefore the markedly decreased secretion of ghrelin could be of particular important for the decreased appetite and improved glucose tolerance seen after LSG.

Eligibility criteria: Inclusion Criteria:

* The Danish national inclusion criteria for bariatric surgery
* Signed written informed consent
* Fasting plasma glucose \<6.1 mmol/l

Exclusion Criteria:

* Pregnancy or breastfeeding.
* Hemoglobin \<6.5 mM
* Newly emerged serious disease

Primary outcomes:
measure: Ad libitum
timeFrame: 240 minutes
Secondary outcomes:
measure: Ad libitum
timeFrame: 240 minutes
measure: Ghrelin
timeFrame: 240 minutes
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Endocrinology, Hvidovre University Hospital
state: Hvidovre
Study officials:
affiliation: Department of Endocrinology, Hvidovre University Hospital, Denmark
name: Nora Hedbäck, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02342925: A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2015-01-21
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER

Brief summary: This single-center, non-randomized, open-label, two treatment, two period, fixed sequence crossover study will investigate the effect of RG1662 treatment on the activity of key renal transporters in healthy male and female participants using metformin. The effect of RG1662 on other renal function parameters will also be explored.


Eligibility criteria: Inclusion Criteria:

* Healthy male or female participants, aged 18 to 60 years, inclusive
* A body mass index between 18 to 32 kg/m2, inclusive
* Informed consent and agreement to comply with study restrictions

Exclusion Criteria:

* A history of epilepsy, convulsions or significant head injury
* Significant history of drug allergy or a known hypersensitivity to any of the ingredients of any of the study treatments
* Pregnant or lactating
* Impaired renal function or clinically relevant hematuria
* A history of lactic acidosis, or risk factors for lactic acidosis
* Any other clinically relevant abnormalities, concomitant diseases or ongoing medical conditions

Primary outcomes:
measure: Pharmacokinetic parameters of metformin derived from plasma and urine concentrations of metformin: area under the concentration-time curve (AUC), maximum concentration (Cmax), renal clearance (CLr) [composite outcome measure]
timeFrame: Up to 9 weeks
Secondary outcomes:
measure: Pharmacokinetic parameters derived from plasma concentrations of RG1662: AUC, Cmax, time to maximum concentration (Tmax), and minimum concentration (Ctrough)[composite outcome measure]
timeFrame: Up to 9 weeks
measure: Pharmacodynamics: renal function measured by derivation of glomerular filtration rate (GFR) from plasma concentrations of iohexol.
timeFrame: Up to 9 weeks
measure: Incidence of adverse events (AEs)
timeFrame: Up to 9 weeks
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00000325: Psychostimulant Abuse - Novel Treatment Approaches - 1
Official title: Psychostimulant Abuse - Novel Treatment Approaches
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cocaine-Related Disorders
Keywords: cocaine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: Mclean Hospital
First posted: 1999-09-21
Enrollment: 0
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To determine if acute assessments of profasi and factrel affect plasma cocaine levels and cocaine-induced behavioral changes in men.


Eligibility criteria: Please contact site for information.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Belmont
country: United States
facility: McLean Hospital, Dept. of Psychiatry
state: Massachusetts
Study officials:
affiliation: Mclean Hospital
name: Jack Mendelson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01893125: Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy
Official title: A Randomised Three Week Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetic Peripheral Neuropathy
Lead sponsor: Convergence Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2013-07-08
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in diabetic peripheral neuropathy (DPN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline period.

Detailed description: A 3 week randomised crossover study to investigate the effect of repeat oral dosing of CNV2197944 75 mg tid versus placebo for on the pain experienced in diabetic peripheral neuropathy (DPN). Each 3 week treatment period is seperated by a 2 week washout period. The primary outcome measure is the change from baseline in the PI-NRS after three weeks of treatment. Secondary outcome measures include pain responder rates, clinical and patient global impressions of pain, and the Neuropathic Pain Symptom Inventory.

Eligibility criteria: Inclusion Criteria:

* Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent
* Diabetes Mellitus (Type I or II)with HbA1c \<9%
* Evidence of symmetrical bilateral pain in lower limbs with evidence of decreased sensation or impaired reflexes and a Michigan Neuropathy Screening -Instrument score of \>3 on physical examination
* Patients with diabetic peripheral neuropathy (DPN) with pain at screening present for more than 6 months. The maximum duration of DPN will be no longer than 5 years

Exclusion Criteria:

* Patients having other severe pain, which may impair the self-assessment of the pain due to DPN
* Patients who have received nerve blocks for neuropathic pain within 4 weeks -Patients on other concomitant medications used to relieve the pain of DPN
* Patients with a documented failure to respond to a maximally tolerated dose regimen of gabapentin or pregabalin

Primary outcomes:
measure: Pain Intensity Numerical Rating Scale
timeFrame: 21 days
Secondary outcomes:
measure: Pain Responder rates
timeFrame: 21 days
measure: Neuropathic Pain Symptom Inventory
timeFrame: 21 days
Other outcomes:
Locations:
city: Gyor
country: Hungary
facility: Petz Aladar County Teaching Hospital
Study officials:
affiliation: Dept. Metabolism and Diabetes, Gyor, Hungary
name: Tibor Hidvegi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00708825: Reverse-Loop Upper Arm Arteriovenous Graft
Official title: Reverse-Loop Upper Arm Arteriovenous Graft for Chronic Hemodialysis
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Blood Vessel Prosthesis
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
Collaborators: name: Min-Sheng General Hospital
First posted: 2008-07-02
Enrollment: 7
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: uremic patient, compromized forarm and elbow options

Brief summary: Background: A conventional configured prosthetic arteriovenous graft (AVG) usually wastes most upper arm vessels that a reverse-loop design may conserve. This study examined the feasibility of the AVG construction and its outcome.

Methods: Retrospective review of clinical outcomes of reverse-loop upper arm AVG patients. Measures included hemodialysis function, duplex scan, procedural complications, and follow-up interventions


Eligibility criteria: Inclusion Criteria:

* compromized forearm and elbow options

Exclusion Criteria:

* unstable

Primary outcomes:
measure: functional event-free primary patency
timeFrame: event-free time
Secondary outcomes:
measure: Measures included hemodialysis function, duplex scan, procedural complications, and follow-up interventions.
timeFrame: events (month)
Other outcomes:
Locations:
city: Pan-Chiao
country: Taiwan
facility: Far Eastern Memorial Hospital
state: Taipei
Study officials:
affiliation: Far Eastern Memorial Hospital
name: Chih-Yang Chan, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: